

## Biovian Announces Antti Nieminen as Chief Executive Officer

Biovian Oy announces that its Board of Directors has named Antti Nieminen, as a Chief Executive Officer, effective January 1<sup>st</sup>, 2022. Nieminen succeeds Co-Founder Dr. Knut Ringbom, who will transition to Senior Advisor of Biovian, after serving 9 years as CEO and a total of 19 years at Biovian since the foundation of the company.

Mr. Nieminen, 46, is one of the Co-Founders of Biovian and served as a Director, Business Development and Projects in his previous role. During his 19 years career in the contract development and manufacturing of biopharmaceuticals, he has contributed to the growth of the company through his biotechnology and CDMO sector expertise and passion to deliver exceptional client service.

**Pierre Remy**, Chairman of the Board, commented, *“Antti Nieminen with his extensive background in contract development and manufacturing of biopharmaceuticals and business development skills is the perfect person to take over the role of the CEO of Biovian. We thank Knut for his great achievements with Biovian and look forward to working closely with Antti to ensure the continued success and growth of Biovian in the years ahead.”*

**Antti Nieminen** commented, *“I am honored and humbled to accept this responsibility and excited to step into the role of a CEO to continue Biovian’s journey from the excellent point where it has got under Knut’s command”. During my years with Biovian, I have worked as a senior scientist, project management, and in business development and sales. This holistic overview and two decades of history within the CDMO business provide good grounds for further developing the company. It is great to be able to continue working together with Knut as an advisor for the management team. We have firm plans to expand our capacities and to solidify Biovian’s position as a trusted, quality player in the CDMO market with a clear focus on Viral vectors and recombinant proteins.*

### About Biovian

Biovian is a Contract Development and Manufacturing Organization, CDMO, that provides premium services to biotech companies developing innovative gene therapies or biopharmaceuticals. The goal of the company is to turn ideas into products by taking client projects from the laboratory bench to the clinic. Biovian offers its clients One-Stop-Shop GMP CDMO services, with modularity available from gene to finished vial. Biovian is especially focusing on Viral Vector production, microbial production of recombinant proteins, and on GMP plasmid DNA. Guided by its Nordic ethos, Biovian has established a reputation for delivering high-quality work on time and within budget to a global client base. Additional information is available at <https://biovian.com/>